Destiny Pharma (DEST) RNS Announcements

Add to Alert list
Date Time Source Announcement
06 Nov 2019 07:00 AM
RNS
Destiny Pharma to present at World AMR Congress
16 Oct 2019 07:00 AM
RNS
Positive phase 1 results published in journal
23 Sep 2019 07:00 AM
RNS
Directorate Change
23 Sep 2019 07:00 AM
RNS
Interim Results for 6 months ended 30 June 2019
12 Sep 2019 07:00 AM
RNS
Notice of Results
10 Sep 2019 07:00 AM
RNS
University of Sheffield Research Collaboration
02 Sep 2019 07:00 AM
RNS
XF Drug platform data presented at EuroBiofilms
15 Aug 2019 12:20 PM
RNS
Holding(s) in Company
31 Jul 2019 07:00 AM
RNS
Presentation at Gordon Research Conference
19 Jul 2019 03:12 PM
RNS
Holding(s) in Company
04 Jun 2019 02:39 PM
RNS
Grant of Options
04 Jun 2019 12:06 PM
RNS
Result of AGM
09 May 2019 02:06 PM
RNS
Appointment of NOMAD and Joint Broker
29 Apr 2019 02:28 PM
RNS
Posting of Annual Report and Notice of AGM
09 Apr 2019 07:00 AM
RNS
Final Results
05 Apr 2019 05:06 PM
RNS
Exercise of Options
01 Apr 2019 03:03 PM
RNS
Exercise of Options
28 Mar 2019 06:13 PM
RNS
Exercise of Options
27 Mar 2019 07:00 AM
RNS
MedPharm to develop new XF-drug formulations
22 Mar 2019 09:47 AM
RNS
Notice of Results
06 Mar 2019 06:00 PM
RNS
Exercise of Options
28 Jan 2019 07:00 AM
RNS
Second positive phase 1 trial data for XF-73
25 Jan 2019 07:00 AM
RNS
New grant awarded under UK-China AMR programme
24 Jan 2019 11:50 AM
RNS
Destiny Pharma notes UK 5-year action plan on AMR
01 Nov 2018 07:00 AM
RNS
Research collaboration with Southampton University
25 Oct 2018 04:05 PM
RNS
Grant of Options
25 Oct 2018 07:00 AM
RNS
Directorate Change
24 Oct 2018 07:00 AM
RNS
UK government highlights global threat of AMR
19 Oct 2018 07:00 AM
RNS
BIA celebrates UK bioscience innovative
26 Sep 2018 07:00 AM
RNS
Dr Jesús González appointed Chief Medical Officer
26 Sep 2018 07:00 AM
RNS
Interim results for six months ended 30 June 2018
06 Sep 2018 07:00 AM
RNS
Directorate Change
26 Jul 2018 07:00 AM
RNS
Positive Phase 1 skin irritation study with XF-73
17 Jul 2018 07:00 AM
RNS
Research collaboration with Aston University
11 Jul 2018 07:00 AM
RNS
Notice of Results
21 Jun 2018 07:00 AM
RNS
Directorate Change
14 Jun 2018 07:00 AM
RNS
Destiny Pharma notes FDA statement on AMR focus
05 Jun 2018 12:47 PM
RNS
Director/PDMR Shareholding
31 May 2018 12:30 PM
RNS
Result of AGM
30 May 2018 07:00 AM
RNS
Destiny Establishes Scientific Advisory Board
23 Apr 2018 07:00 AM
RNS
Posting of Annual Report and Notice of AGM
12 Apr 2018 07:00 AM
RNS
Destiny Pharma announces clinical update on XF-73
12 Apr 2018 07:00 AM
RNS
Final Results
23 Mar 2018 07:00 AM
RNS
Notice of Full Year Results
22 Mar 2018 07:00 AM
RNS
Appointment of Joint Broker
15 Mar 2018 07:00 AM
RNS
FDA Fast Track Designation for lead drug XF-73
26 Feb 2018 07:00 AM
RNS
Destiny Pharma opens IND ahead of XF-73 US trials
11 Jan 2018 07:00 AM
RNS
Participating in Cantor Antibiotics Summit panel
29 Dec 2017 07:00 AM
RNS
Total Voting Rights
07 Dec 2017 09:59 AM
RNS
Holding(s) in Company

Destiny Pharma is a biotechnology company that develops and sells new medicines to prevent serious infections.

Destiny Pharma share price launched on AIM on August 18, 2017.

UK 100